Birgitte Klug Albertsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Birgitte Klug Albertsen has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Kjeld Schmiegelow
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark
12 shared publications - Line Stensig Lynggaard
Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
7 shared publications Kjeld Schmiegelow
Department of Pediatrics and Adolescent Medicine Rigshospitalet, University of Copenhagen Copenhagen Denmark
6 shared publicationsPeder Skov Wehner
Department of Paediatric Haematology and Oncology, H.C. Andersen Children's Hospital Odense University Hospital Odense Denmark
5 shared publications- Sofie Gottschalk Højfeldt
Department of Pediatrics and Adolescent Medicine Aarhus University Hospital, and Department of Clinical Medicine Aarhus University Aarhus Denmark
5 shared publications - Thomas Leth Frandsen
Mary Elizabeth’s Hospital and Juliane Marie Centre, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
5 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1)
Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications
Purpose: Tyrosine kinase inhibitors (TKIs) have improved outcomes in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and are increasingly incorporated into treatment protocols of Philadelphia chromosome-like (Ph-like, ABL-class) ALL. However, central nervous system (CNS) relapse remains a significant challenge. Imatinib, a first-generation TKI, demonstrates limited CNS penetration in adults, yet data in children are sparse. Methods: This prospective, multicenter study investigated cerebrospinal fluid (CSF) and matched plasma concentrations of imatinib and its primary bioactive metabolite (N-desmethyl-imatinib) in children and young adults with Ph + or Ph-like (ABL-class) ALL. Plasma and CSF samples were analyzed with liquid chromatography tandem mass spectrometry (LC-MS/MS). Linear mixed-effects models were used to assess concentrations across compartments and over time. Results: Between January 2023 and June 2025, 32 paired plasma and CSF samples were collected from ten patients (range 1–8 samples/patient; median: 3). In total, 78% of plasma imatinib concentrations were above 1,000 ng/mL. On average, plasma imatinib concentrations were 189-fold higher than in CSF (geometric mean ratio, 95% CI: 142–249, p < 0.001), which was even more profound for N-desmethyl-imatinib (geometric mean ratio 273, 95% CI: 218–339, p < 0.001). The highest measured CSF-imatinib concentration was 63 ng/mL. During therapy, both plasma and CSF imatinib concentrations declined at an average of 0.32% per day ( p < 0.001), resulting in stable CSF-to-plasma ratio over a median follow-up of 5.7 months (range: 0–14 months). Conclusion: The very low CSF concentrations support the rationale for alternative TKIs with improved CNS distribution in patients at risk of CNS relapse.
- 19 June 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1)
Open AccessCentral nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications
Purpose: Tyrosine kinase inhibitors (TKIs) have improved outcomes in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and are increasingly incorporated into treatment protocols of Philadelphia chromosome-like (Ph-like, ABL-class) ALL. However, central nervous system (CNS) relapse remains a significant challenge. Imatinib, a first-generation TKI, demonstrates limited CNS penetration in adults, yet data in children are sparse. Methods: This prospective, multicenter study investigated cerebrospinal fluid (CSF) and matched plasma concentrations of imatinib and its primary bioactive metabolite (N-desmethyl-imatinib) in children and young adults with Ph + or Ph-like (ABL-class) ALL. Plasma and CSF samples were analyzed with liquid chromatography tandem mass spectrometry (LC-MS/MS). Linear mixed-effects models were used to assess concentrations across compartments and over time. Results: Between January 2023 and June 2025, 32 paired plasma and CSF samples were collected from ten patients (range 1–8 samples/patient; median: 3). In total, 78% of plasma imatinib concentrations were above 1,000 ng/mL. On average, plasma imatinib concentrations were 189-fold higher than in CSF (geometric mean ratio, 95% CI: 142–249, p < 0.001), which was even more profound for N-desmethyl-imatinib (geometric mean ratio 273, 95% CI: 218–339, p < 0.001). The highest measured CSF-imatinib concentration was 63 ng/mL. During therapy, both plasma and CSF imatinib concentrations declined at an average of 0.32% per day ( p < 0.001), resulting in stable CSF-to-plasma ratio over a median follow-up of 5.7 months (range: 0–14 months). Conclusion: The very low CSF concentrations support the rationale for alternative TKIs with improved CNS distribution in patients at risk of CNS relapse.
- Open Access
- 18 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 618
Assessment of PEG-Asparaginase and Erwinia Asparaginase Activity Under Variable Storage Conditions
Background: PEG-Asparaginase and Erwinia asparaginase are enzyme-based anticancer therapies used in the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL), where adequate plasma enzyme activity is required for therapeutic efficacy. In many study groups, therapeutic drug monitoring is routinely applied due to pharmacokinetic variability and the risk of hypersensitivity reactions followed by increased clearance and insufficient treatment. In clinical practice, samples may be exposed to prolonged transport and variable pre-analytical conditions. Knowledge on pre-analytical stability is important for correct interpretation of PEG-Asparaginase and Erwinia asparaginase activity in plasma. This study aimed to evaluate the in vitro stability of PEG-Asparaginase and Erwinia asparaginase under pre-analytical conditions. Methods: Three experimental stability studies were conducted at two activity levels. Enzyme stability in plasma was assessed during storage at 4 °C and 20 °C for up to 14 days and following three freeze–thaw cycles. Stability in whole blood prior to centrifugation was evaluated over 24 h. Enzyme activity was measured using a validated spectrophotometric assay, and stability was defined as a deviation within ±15% of baseline activity. Results: Both enzymes remained stable in plasma for up to 14 days at 4 °C and 20 °C, and no clinically relevant reduction in enzyme activity of freeze–thaw cycling was observed. In whole blood, Erwinia asparaginase and high-activity PEG-Asparaginase remained stable for 24 h at 20 °C, whereas low-activity PEG-Asparaginase showed a reduction in activity of approximately 22%, mainly within the first two hours. Conclusions: PEG-Asparaginase and Erwinia asparaginase are stable in plasma for up to 14 days at room temperature, enabling shipment of plasma samples by mail. However, prompt centrifugation is recommended for samples with low PEG-Asparaginase activity to ensure accurate therapeutic drug monitoring.
- 18 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 618
Open AccessAssessment of PEG-Asparaginase and Erwinia Asparaginase Activity Under Variable Storage Conditions
Background: PEG-Asparaginase and Erwinia asparaginase are enzyme-based anticancer therapies used in the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL), where adequate plasma enzyme activity is required for therapeutic efficacy. In many study groups, therapeutic drug monitoring is routinely applied due to pharmacokinetic variability and the risk of hypersensitivity reactions followed by increased clearance and insufficient treatment. In clinical practice, samples may be exposed to prolonged transport and variable pre-analytical conditions. Knowledge on pre-analytical stability is important for correct interpretation of PEG-Asparaginase and Erwinia asparaginase activity in plasma. This study aimed to evaluate the in vitro stability of PEG-Asparaginase and Erwinia asparaginase under pre-analytical conditions. Methods: Three experimental stability studies were conducted at two activity levels. Enzyme stability in plasma was assessed during storage at 4 °C and 20 °C for up to 14 days and following three freeze–thaw cycles. Stability in whole blood prior to centrifugation was evaluated over 24 h. Enzyme activity was measured using a validated spectrophotometric assay, and stability was defined as a deviation within ±15% of baseline activity. Results: Both enzymes remained stable in plasma for up to 14 days at 4 °C and 20 °C, and no clinically relevant reduction in enzyme activity of freeze–thaw cycling was observed. In whole blood, Erwinia asparaginase and high-activity PEG-Asparaginase remained stable for 24 h at 20 °C, whereas low-activity PEG-Asparaginase showed a reduction in activity of approximately 22%, mainly within the first two hours. Conclusions: PEG-Asparaginase and Erwinia asparaginase are stable in plasma for up to 14 days at room temperature, enabling shipment of plasma samples by mail. However, prompt centrifugation is recommended for samples with low PEG-Asparaginase activity to ensure accurate therapeutic drug monitoring.
- Open Access
- 10 February 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (3) , 630-637
Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study
With increasing survival in acute lymphoblastic leukemia (ALL), long-term toxicities have become a critical aspect. A novel measure, designated Severe Toxicity-free survival (STFS), was developed through international consensus to integrate the most severe, symptomatic organ toxicities in outcome evaluation. This measure has not been applied to real-world data before. We assessed the incidence of 21 predefined Severe Toxicities in a nationwide cohort of 506 ALL patients aged 1–45 years treated according to the NOPHO ALL2008 protocol. At five years, event-free survival was 84.4% (95% CI: 81.3–87.7%) and Severe Toxicity-event-free survival was 78.4% (95% CI: 74.9–82.1%), with significantly lower values in adults (aged 18–45 years) than children (61.6% [52.6–72.2%] vs 82.4% [78.8–86.2%]; log-rank p < 0.001). The most common Severe Toxicities were severe osteonecrosis limiting activities of daily function ( N = 20) and disabling paralytic and neuropathic conditions ( N = 16). Exploratory analyses showed that 10–17-year-olds had the highest risk of Severe Toxicities similar to that of adults. These findings highlight a burden of severe, long-term toxicities in ALL survivors overlooked by traditional outcome measures, also following frontline therapy only. STFS should be incorporated in future trials for meaningful outcome evaluation and international comparisons across treatment strategies.
- 10 February 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (3) , 630-637
Open AccessSevere toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study
With increasing survival in acute lymphoblastic leukemia (ALL), long-term toxicities have become a critical aspect. A novel measure, designated Severe Toxicity-free survival (STFS), was developed through international consensus to integrate the most severe, symptomatic organ toxicities in outcome evaluation. This measure has not been applied to real-world data before. We assessed the incidence of 21 predefined Severe Toxicities in a nationwide cohort of 506 ALL patients aged 1–45 years treated according to the NOPHO ALL2008 protocol. At five years, event-free survival was 84.4% (95% CI: 81.3–87.7%) and Severe Toxicity-event-free survival was 78.4% (95% CI: 74.9–82.1%), with significantly lower values in adults (aged 18–45 years) than children (61.6% [52.6–72.2%] vs 82.4% [78.8–86.2%]; log-rank p < 0.001). The most common Severe Toxicities were severe osteonecrosis limiting activities of daily function ( N = 20) and disabling paralytic and neuropathic conditions ( N = 16). Exploratory analyses showed that 10–17-year-olds had the highest risk of Severe Toxicities similar to that of adults. These findings highlight a burden of severe, long-term toxicities in ALL survivors overlooked by traditional outcome measures, also following frontline therapy only. STFS should be incorporated in future trials for meaningful outcome evaluation and international comparisons across treatment strategies.
- Open Access
- 18 November 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (11) , e71389
Physical Functioning Report and Pulmonary Function Deficit in Childhood and Adolescent Acute Lymphoblastic Leukemia Survivors: A National Cross‐Sectional ALL‐STAR Lungs Study
Background: Childhood acute lymphoblastic leukemia (ALL) survivors face an increased risk of pulmonary function deficit (PFD), which may affect physical functioning. We aimed to evaluate parent proxy‐ and self‐reported physical functioning and the association with PFD and abnormal bronchodilator response ( + BDR) among survivors versus controls. Methods: This cross‐sectional study (February 2019–May 2024) included N = 184 ALL survivors (aged 5–17.9 years) from a national NOPHO ALL2008 protocol‐treated cohort (eligible, N = 295) ( ≥ 1 year after treatment cessation) and 207 controls. Physical functioning was assessed using the Paediatric Quality of Life Inventory (PedsQL) questionnaire. Pulmonary function tests (PFTs) identified PFD (abnormal PFT) and +BDR according to ERS/ATS criteria. Ordinal logistic regression and t‐test compared groups. Results: ALL survivor parents proxy‐reported significantly poorer physical functioning than controls (mean difference [MD] −13.3 95% CI [−16.3; −10.3] to MD −10.3 [−17.2; −3.3], p < 0.001 to p = 0.004), but clinically significant impairments were restricted to parent proxy‐reports from survivors treated with high‐risk (HR) chemotherapy (MD −19.9 [−29.0; −10.7] to −11.5 [−17.5; −5.6], p < 0.001) and stem cell transplantation (HR‐SCT) (MD −24.7 [−30.1; −19.4] to −16.9 [−27.4; −6.5], p < 0.001 to p = 0.002) as well as self‐reports from HR (MD −11.2 [−18.9; −3.4], p = 0.006) and HR‐SCT survivors (MD −14.5 [−24.1; −4.8], p = 0.004). Among 5–15‐year‐olds, PFD/ + BDR was associated with significantly poorer parent proxy‐reported physical functioning in survivors versus controls (MD −14.3 [−21.2; −7.3], p < 0.001). Significant deficits in these groups related to running, engaging in sports/exercise and lifting heavy objects. PFD/ + BDR was not associated with poorer physical functioning reports within survivors (MD −2.5 [−9.0; 3.3] to 0.1 [−13.7; 13.8], p = 0.36–0.99). Conclusions: Physical functioning in survivors compared to controls varies with intensity of treatment, most evident in HR and HR‐SCT survivors, with impairments linked to PFD and +BDR in the youngest. Among survivors, physical functioning did not align with PFD and +BDR status, highlighting the need for parallel assessment of objective and subjective measures during follow‐up. Baseline PFT and tailored follow‐up are essential for high‐risk groups, to detect PFD early and intervene.
- 18 November 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (11) , e71389
Open AccessPhysical Functioning Report and Pulmonary Function Deficit in Childhood and Adolescent Acute Lymphoblastic Leukemia Survivors: A National Cross‐Sectional ALL‐STAR Lungs Study
Background: Childhood acute lymphoblastic leukemia (ALL) survivors face an increased risk of pulmonary function deficit (PFD), which may affect physical functioning. We aimed to evaluate parent proxy‐ and self‐reported physical functioning and the association with PFD and abnormal bronchodilator response ( + BDR) among survivors versus controls. Methods: This cross‐sectional study (February 2019–May 2024) included N = 184 ALL survivors (aged 5–17.9 years) from a national NOPHO ALL2008 protocol‐treated cohort (eligible, N = 295) ( ≥ 1 year after treatment cessation) and 207 controls. Physical functioning was assessed using the Paediatric Quality of Life Inventory (PedsQL) questionnaire. Pulmonary function tests (PFTs) identified PFD (abnormal PFT) and +BDR according to ERS/ATS criteria. Ordinal logistic regression and t‐test compared groups. Results: ALL survivor parents proxy‐reported significantly poorer physical functioning than controls (mean difference [MD] −13.3 95% CI [−16.3; −10.3] to MD −10.3 [−17.2; −3.3], p < 0.001 to p = 0.004), but clinically significant impairments were restricted to parent proxy‐reports from survivors treated with high‐risk (HR) chemotherapy (MD −19.9 [−29.0; −10.7] to −11.5 [−17.5; −5.6], p < 0.001) and stem cell transplantation (HR‐SCT) (MD −24.7 [−30.1; −19.4] to −16.9 [−27.4; −6.5], p < 0.001 to p = 0.002) as well as self‐reports from HR (MD −11.2 [−18.9; −3.4], p = 0.006) and HR‐SCT survivors (MD −14.5 [−24.1; −4.8], p = 0.004). Among 5–15‐year‐olds, PFD/ + BDR was associated with significantly poorer parent proxy‐reported physical functioning in survivors versus controls (MD −14.3 [−21.2; −7.3], p < 0.001). Significant deficits in these groups related to running, engaging in sports/exercise and lifting heavy objects. PFD/ + BDR was not associated with poorer physical functioning reports within survivors (MD −2.5 [−9.0; 3.3] to 0.1 [−13.7; 13.8], p = 0.36–0.99). Conclusions: Physical functioning in survivors compared to controls varies with intensity of treatment, most evident in HR and HR‐SCT survivors, with impairments linked to PFD and +BDR in the youngest. Among survivors, physical functioning did not align with PFD and +BDR status, highlighting the need for parallel assessment of objective and subjective measures during follow‐up. Baseline PFT and tailored follow‐up are essential for high‐risk groups, to detect PFD early and intervene.
- Open Access
- 7 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 1920-1929
Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study
Summary: Polyethylene glycol (peg)‐asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions. This study aims to comprehensively analyse asparaginase enzyme activity (AEA) pharmacokinetics, validate a previously developed pharmacokinetic model based on intravenous administration and evaluate its capability to detect changes in clearance before inactivation in patients treated with intramuscular peg‐asparaginase. The study, covering 644 patients aged 1–45 with ALL under the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 Protocol (February 2017–December 2022, in Nordic and Baltic countries), included 3003 AEA samples. Sampling occurred 14 days post peg‐asparaginase doses, with additional sampling between doses. The incidence of inactivation was 15.2%. Utilizing the pharmacokinetic model, estimates revealed an 87.8% sensitivity and 65.5% specificity for detecting increased peg‐asparaginase clearance over time in patients experiencing inactivation. Identification of increased clearance preceding inactivation in the NOPHO ALL2008 dataset highlights the potential of pharmacokinetic sampling to predict inactivation and enable timely intervention before clinical manifestation, with further refinement and inclusion of additional protocols into a unified model offering the promise of improving clinicians' ability to assess individual patient risk.
- 7 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 1920-1929
Open AccessEarly prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study
Summary: Polyethylene glycol (peg)‐asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions. This study aims to comprehensively analyse asparaginase enzyme activity (AEA) pharmacokinetics, validate a previously developed pharmacokinetic model based on intravenous administration and evaluate its capability to detect changes in clearance before inactivation in patients treated with intramuscular peg‐asparaginase. The study, covering 644 patients aged 1–45 with ALL under the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 Protocol (February 2017–December 2022, in Nordic and Baltic countries), included 3003 AEA samples. Sampling occurred 14 days post peg‐asparaginase doses, with additional sampling between doses. The incidence of inactivation was 15.2%. Utilizing the pharmacokinetic model, estimates revealed an 87.8% sensitivity and 65.5% specificity for detecting increased peg‐asparaginase clearance over time in patients experiencing inactivation. Identification of increased clearance preceding inactivation in the NOPHO ALL2008 dataset highlights the potential of pharmacokinetic sampling to predict inactivation and enable timely intervention before clinical manifestation, with further refinement and inclusion of additional protocols into a unified model offering the promise of improving clinicians' ability to assess individual patient risk.
- Open Access
Strength Training Exercises to minimise late Effects of childhood Leukaemia or lymphoma among adolescents – The STEEL study – protocol for a national multicentre randomised controlled trial
Background: Adolescent cancer survivors (ACS) often experience long-term impairments in muscle strength, physical function, and quality of life. Strength training may help address these deficits, but there is limited evidence from randomised trials. This study investigates the efficacy of progressive strength training compared to low-load circuit training in increasing muscle strength over 16 weeks among ACS. Methods: In this multicentre randomised controlled trial, we will recruit 60 ACS successfully treated for acute lymphoblastic leukaemia or lymphoma. Participants aged 10–19 years are recruited from paediatric oncology departments across Denmark. They are randomised stratified by sex to either: 1. a 16-week partly supervised progressive strength training programme (STEEL) with individually tailored exercises targeting major muscle groups, progressing in load and volume over time; or 2. a 16-week partly supervised circuit training programme involving aerobic and low-load strength exercises. The primary outcomes are the change in isometric muscle strength in elbow flexion and extension, and knee flexion and extension from baseline to the 16-week follow-up. Secondary outcomes include physical function (dynamic strength, rate of force development, grip strength, and walking endurance), health-related quality of life, metabolic markers, bone mineral density, movement-evoked pain, exercise compliance and fidelity, physical activity level, and participant satisfaction. Discussion: This trial addresses the need for evidence-based rehabilitation strategies in ACS. It is designed to detect short-term effects of supervised strength training on key physical health outcomes using a robust, blinded, and clinically relevant comparison. Results may inform future survivorship care and guidelines. Trial Registration: ClinicalTrials.gov identifier: NCT05673152 . Registered January 4, 2023.
Open AccessStrength Training Exercises to minimise late Effects of childhood Leukaemia or lymphoma among adolescents – The STEEL study – protocol for a national multicentre randomised controlled trial
Background: Adolescent cancer survivors (ACS) often experience long-term impairments in muscle strength, physical function, and quality of life. Strength training may help address these deficits, but there is limited evidence from randomised trials. This study investigates the efficacy of progressive strength training compared to low-load circuit training in increasing muscle strength over 16 weeks among ACS. Methods: In this multicentre randomised controlled trial, we will recruit 60 ACS successfully treated for acute lymphoblastic leukaemia or lymphoma. Participants aged 10–19 years are recruited from paediatric oncology departments across Denmark. They are randomised stratified by sex to either: 1. a 16-week partly supervised progressive strength training programme (STEEL) with individually tailored exercises targeting major muscle groups, progressing in load and volume over time; or 2. a 16-week partly supervised circuit training programme involving aerobic and low-load strength exercises. The primary outcomes are the change in isometric muscle strength in elbow flexion and extension, and knee flexion and extension from baseline to the 16-week follow-up. Secondary outcomes include physical function (dynamic strength, rate of force development, grip strength, and walking endurance), health-related quality of life, metabolic markers, bone mineral density, movement-evoked pain, exercise compliance and fidelity, physical activity level, and participant satisfaction. Discussion: This trial addresses the need for evidence-based rehabilitation strategies in ACS. It is designed to detect short-term effects of supervised strength training on key physical health outcomes using a robust, blinded, and clinically relevant comparison. Results may inform future survivorship care and guidelines. Trial Registration: ClinicalTrials.gov identifier: NCT05673152 . Registered January 4, 2023.
- Open Access
- 29 April 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31705
Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study
Background: Metabolic syndrome (MetS), a risk factor for early cardiovascular morbidity and mortality, is seen in up to 34% of survivors of childhood acute lymphoblastic leukemia (ALL). Procedure: We performed a Danish, national cross‐sectional study of ALL survivors (aged 1–45 years at diagnosis) treated according to the NOPHO ALL2008 protocol, examined at least 1 year after treatment cessation. The study included non‐cancer community controls, matched on sex and age. We explored the prevalence and components of the MetS criteria (hyperglycemia, hypertension, increased waist circumference (WC), and dyslipidemia) and glucose homeostasis (insulin and C‐peptide). Results: We included 366 survivors of ALL (participation rate 84%) and 368 controls. Median age (IQR) at follow‐up examination was 14.1 (10.8–21.8) years, and follow‐up time after the ALL diagnosis was 6.9 (4.7–9.1). The prevalence of MetS in survivors was 7.6% and in controls 3.8 % ( p = 0.039). The increased MetS prevalence was driven by ALL patients undergoing total body irradiation (TBI), and age and body mass index (BMI) percentile ≥95 at diagnosis ( p ≤ 0.01). The MetS prevalence in non‐TBI patients did not differ from controls ( p = 0.43), but non‐TBI patients more often fulfilled the MetS criteria WC and/or elevated high‐density lipoprotein ( p < 0.03). Survivors had higher serum insulin and C‐peptide than controls ( p < 0.01). Conclusions: ALL survivors have an increased risk of MetS compared with controls, essentially driven by the patients treated with TBI. The MetS frequency in non‐TBI patients is equal to controls, but non‐TBI patients more often have one or two components of Mets. ALL survivors seem slightly more insulin‐resistant than controls.
- 29 April 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31705
Open AccessRisk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study
Background: Metabolic syndrome (MetS), a risk factor for early cardiovascular morbidity and mortality, is seen in up to 34% of survivors of childhood acute lymphoblastic leukemia (ALL). Procedure: We performed a Danish, national cross‐sectional study of ALL survivors (aged 1–45 years at diagnosis) treated according to the NOPHO ALL2008 protocol, examined at least 1 year after treatment cessation. The study included non‐cancer community controls, matched on sex and age. We explored the prevalence and components of the MetS criteria (hyperglycemia, hypertension, increased waist circumference (WC), and dyslipidemia) and glucose homeostasis (insulin and C‐peptide). Results: We included 366 survivors of ALL (participation rate 84%) and 368 controls. Median age (IQR) at follow‐up examination was 14.1 (10.8–21.8) years, and follow‐up time after the ALL diagnosis was 6.9 (4.7–9.1). The prevalence of MetS in survivors was 7.6% and in controls 3.8 % ( p = 0.039). The increased MetS prevalence was driven by ALL patients undergoing total body irradiation (TBI), and age and body mass index (BMI) percentile ≥95 at diagnosis ( p ≤ 0.01). The MetS prevalence in non‐TBI patients did not differ from controls ( p = 0.43), but non‐TBI patients more often fulfilled the MetS criteria WC and/or elevated high‐density lipoprotein ( p < 0.03). Survivors had higher serum insulin and C‐peptide than controls ( p < 0.01). Conclusions: ALL survivors have an increased risk of MetS compared with controls, essentially driven by the patients treated with TBI. The MetS frequency in non‐TBI patients is equal to controls, but non‐TBI patients more often have one or two components of Mets. ALL survivors seem slightly more insulin‐resistant than controls.
- Open Access
- 21 April 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (7) , e31018
Quality of life in children and adolescents after treatment for acute lymphoblastic leukemia according to the NOPHO ALL2008 protocol
Background: The improved outcome of childhood acute lymphoblastic leukemia (ALL) over the last decades has increased the importance of assessing late effects and health‐related quality of life (HRQoL), particularly when evaluating and comparing outcomes in clinical trials. This study aimed to assess HRQoL in children treated for ALL according to the NOPHO ALL2008 protocol. Procedure: Children, aged 1 to less than 18 years at diagnosis, alive in first remission, and their parents, were asked to complete PedsQL 4.0 Generic Core Scales (self‐ and proxy‐report) at ≥6 months after end of therapy. Data on socioeconomic factors and parent‐reported toxicity were collected through a study‐specific questionnaire, and the NOPHO ALL2008 database was used to identify eligible families and add additional disease‐ and treatment‐related data. HRQoL data were collected during 2013–2019 in Sweden, Finland, and Denmark. Results: A total of 299 children were included. The older children (8 years and older) reported similar HRQoL scores compared to Finnish reference data, except lower scores for School Functioning in high‐risk patients. Scores from the parent‐proxy and self‐reports from 5–7‐year olds were notably lower than reference. Parent‐reported toxicity was associated with lower total and physical HRQoL scores in adjusted models for younger as well as older children in the self‐report and parent‐proxy versions, and also with lower psychosocial score in the parent‐proxy. Conclusions: Self‐reported HRQoL was similar to reference population. The most important determinant for HRQoL after end of ALL treatment was parent‐reported toxicity during treatment. Thus, minimizing complications is an obvious focus for future treatment protocols.
- 21 April 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (7) , e31018
Open AccessQuality of life in children and adolescents after treatment for acute lymphoblastic leukemia according to the NOPHO ALL2008 protocol
Background: The improved outcome of childhood acute lymphoblastic leukemia (ALL) over the last decades has increased the importance of assessing late effects and health‐related quality of life (HRQoL), particularly when evaluating and comparing outcomes in clinical trials. This study aimed to assess HRQoL in children treated for ALL according to the NOPHO ALL2008 protocol. Procedure: Children, aged 1 to less than 18 years at diagnosis, alive in first remission, and their parents, were asked to complete PedsQL 4.0 Generic Core Scales (self‐ and proxy‐report) at ≥6 months after end of therapy. Data on socioeconomic factors and parent‐reported toxicity were collected through a study‐specific questionnaire, and the NOPHO ALL2008 database was used to identify eligible families and add additional disease‐ and treatment‐related data. HRQoL data were collected during 2013–2019 in Sweden, Finland, and Denmark. Results: A total of 299 children were included. The older children (8 years and older) reported similar HRQoL scores compared to Finnish reference data, except lower scores for School Functioning in high‐risk patients. Scores from the parent‐proxy and self‐reports from 5–7‐year olds were notably lower than reference. Parent‐reported toxicity was associated with lower total and physical HRQoL scores in adjusted models for younger as well as older children in the self‐report and parent‐proxy versions, and also with lower psychosocial score in the parent‐proxy. Conclusions: Self‐reported HRQoL was similar to reference population. The most important determinant for HRQoL after end of ALL treatment was parent‐reported toxicity during treatment. Thus, minimizing complications is an obvious focus for future treatment protocols.
- Open Access
- 13 March 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (6) , e30937
Sequelae and post‐thrombotic syndrome after venous thromboembolism in acute lymphoblastic leukemia survivors treated on the NOPHO ALL2008 protocol
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post‐thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from 0% to 70%, reflecting very heterogenous cohorts and assessment tools. We aimed to estimate sequelae, including PTS and QoL in children and adults (p = .9). This study underscores the need for comprehensive population‐based investigations with validation of PTS instruments in ALL survivors.
- 13 March 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (6) , e30937
Open AccessSequelae and post‐thrombotic syndrome after venous thromboembolism in acute lymphoblastic leukemia survivors treated on the NOPHO ALL2008 protocol
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post‐thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from 0% to 70%, reflecting very heterogenous cohorts and assessment tools. We aimed to estimate sequelae, including PTS and QoL in children and adults (p = .9). This study underscores the need for comprehensive population‐based investigations with validation of PTS instruments in ALL survivors.
- Open Access
- 29 January 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 712-719
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.
- 29 January 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 712-719
Open AccessIncrease in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.